The fluoropyrimidine antimetabolites were employed in a wide range of neoplastic diseases. In particular, 5-fluorouracil in association with other chemotherapeutic agents, or biochemical modulators was successfully used in the treatment of colorectal, gastric, breast, head and neck cancers. With this type of chemotherapy, a response rate ≤ 20% was obtained in gastrointestinal tumors, without a statistically significant impact on the overall survival.
UFT is a combination of tegafur an uracil, which has the important advantage of an improved oral bioavailability, if we compare it with 5-fluorouracil. Uracil, avoiding the fluoropyrimidine degradation inside the tumor cells, increases the permanence of the metabolically active fluropyrimidine into the target cell, so having an improvement in the therapeutic activity.
A very large spectrum of cancers were treated with this molecule. In particular, a response rate in the range of 20–40% was observed in the treatment of patients with metastatic colorectal cancer.
Phase III trials are ongoing to evaluate the advantage on 5-FU of this new fluoropyrimidine in terms of clinical efficacy, and quality of life, considering the possibility to administer it orally.
AlonsoV., SantaderC., FlorianJ., AlonsoM., IslaM.D., EscuderoP., SaenzA., TresA.: Phase II trial of oral tegafur and folinic acid with mitoxantrone as first-line regimen in patients with metastatic breast cancer. Tumori, 82: 61–64, 1996.
2.
BajettaE., CarnaghiC., SommaL., Gallo StampinoC.: A pilot safety study of capecitabine, a new oral fluoropyrimidine, in patients with advanced neoplastic disease. Tumori, 82: 450–452, 1996.
3.
BajettaE., ColleoniM., Di BartolomeoM., BuzzoniR., BozzettiF., DociR., SommaL., CappuzzoF., Gallo StampinoC., GuezziA., BalantL.P., ZilemboN., Di LeoA.: Doxifluridine and leocovorin: An oral treatment combination in advanced colorectal cancer. J. Clin. Oncol., 13: 2613–2619, 1995.
4.
BajettaE., Di BartolomeoM., SommaL., Del VecchioM., ArtaleS., ZuninoF., BignamiP., MaganiE., BuzzoniR.: Doxifluridine in colorectal cancer patients resistant to fluorouracil (5-FU) containing regimens. Eur. J. Cancer, 33: 687–690, 1997.
5.
CaoS., RustumY.M.: 5-fluorouracil prodrug ftorafur, modulated by uracil (UFT): preclinical and clinical prospectives. Tumori (suppl.), 83: S90–S93, 1997.
6.
CohenA.M., MinskyB.D., SchilskyR.L.: Cancer of the colon. In: Cancer: Principles and Practice of Oncology, De VitaV.T., HellmanS., RosenbergS.A. (Eds.), 5th edn., pp. 1144–1197, Lippincott-Raven, Philadelphia, 1997.
7.
ColleoniM., NelliP., ManenteP.: Clinical development of new fluoropyrimidines: A major improvement in colorectal cancer treatment. Tumori, 81: 303–307, 1995.
8.
DanielsM., Diaz-RubioE., GuillemV., MonteroG.M., Garcia-CondeJ., EstapeJ., MartinM., HerranzC., OrdonezA., GalanA.: Phase II trial of UFT activity in pretreated breast cancer patients. Jpn. J. Clin. Oncol., 23: 363–365, 1993.
9.
DirixL.Y., BissetD, Van OosteromA.T., AllmanD.S., OsterwalderB., CassidyJ.: A phase I study of capecitabine in combination with oral leucovorin in patients with advanced and/or metastatic solid cancer (Abst. N. 1821). Proc. Am. Soc. Clin. Oncol., 15: 496, 1996.
10.
FindlayM., Van CutsemE., KochaW., AllmanD., LaffranchiB., GriffinT., OsterwalderB., DalleyD., PazdurR., VerweijJ.: A randomized phase II study of Xeloda™ (capecitabine) in patients with advanced colorectal cancer (Abst. N. 798). Proc. Am. Soc. Clin. Oncol., 16: 227, 1997.
11.
FolkmanJ.: What is the role of thymidine phosphorylase in tumor angiogenesis. J. Natl. Cancer Inst., 88: 1091–1092, 1993.
12.
FriedmanM.A., IgnoffoR.J.: A review of the United States clinical experience of the fluoropyrimidine, ftorafur (NSC-148958). Cancer Treat. Rev., 7: 205–213, 1980.
13.
FujitaK., MunakataA.: Concentration of 5-fluorouracil in renal cells from cancer patients administered a mixture of 1-(2-tetrahydrofuryl)-5-fluorouracil and uracil. Int. J. Clin. Pharmacol. Res., 11: 171–174, 1991.
14.
GemmaA., KudokS., YoshimuraA., OnoY., TakenakaK., HayashimaraK., HinoM., ShibuyaM., NiitaniH.: Pilot trial of a combination comprising of consecutive oral administrations of UFT, and two-divided administrations of CDDP in non-small cell lung cancer. Anticancer Res., 15: 2691–2695, 1995.
15.
HashimotoT., OmuraK., IshidaF., WatanabeY.: Clinical efficacy of cis-diammine-dichloroplatin and 5-fluorouracil (UFT) in advanced cancer of the alimentary tract. Jpn. J. Cancer Chemother., 20: 1338–1348, 1993.
16.
HeidelbergerC., AnsfieldF.J.: Experimental and clinical use of fluorinated pyrimidines in cancer chemotherapy. Cancer Res., 23: 1226–1243, 1963.
17.
HoD.H., CovingtonW.P., PazdurR., BrownN.S., KuritaniG., NewmanR.A., RabberM.N., KrakoffI.H.: Clinical pharmacology of combined oral uracil and ftorafur. Drug Metab. Distrib., 20: 936–940, 1992.
18.
HoriuchiM., InuyamaY., MiyakeH. Head, and Neck UFT Study Group: Efficacy of surgical adjuvant with tegafur and uracil (UFT) in resectable head and neck cancer: a prospective randomized study (Abst. N. 918). Proc. Am. Soc. Clin. Oncol., 13: 284, 1994.
19.
HughesM., PlantingA., TwelvesC., SchellensJ., AllmanD., OsterwalderB., KayeS., VerweijJ.: A phase I study of intermittent twice daily oral therapy with capecitabine in patients with advanced and/or metastatic solid cancer (Abst. N. 297). Ann. Oncol., 7(Suppl. 1): 87, 1996.
20.
IchinoseY., TakanashiN., YanoT., AsohH., YokoyamaH., TayamaK., HaraN., OhtaM.: A phase II trial of oral tegafur and uracil plus cisplatin in patients with inoperable non-small cell lung cancer. Cancer, 75: 2677–2680, 1995.
21.
JinM., YaneB., ZhaneW., WaneY.: High dose mitomycin-C containing regimens in the treatment of advanced gastric cancer. Semin. Surg. Oncol., 10: 114–116, 1994.
22.
KimanK., SuzukiS., SatomiT., SakonjiM., NiheiM., TanakaT., KimijimaI., AbeR.: Efficacy of combination therapy consisting of cyclophosphamide, adriamycin, UFT and oophorectomy/tamoxifen for advanced or recurrent breast cancer. Jpn. J. Cancer Chemother., 21: 2445–2452, 1994.
23.
KojimaJ., KamataT., MonnaT.: Randomized trial comparing UFT and FT in the treatment of advanced hepatocellular carcinoma. Jpn. J. Cancer Chemother., 19: 637–646, 1992.
KunimuneY., MarudenA., TakenouchiT., SutoH., MoritaK., ShimpoK., TanabeT.: Subacute toxicity of UFT, a new anticancer agent orally administered in rats. Pharmacometrics, 20: 1027–1053, 1980.
26.
MalikS.T.A., TalbotD., ClarkeP.I., OsborneR., ReznekR., WrigleyP.F.M., SlevinM.L.: Phase II trial of UFT in advanced colorectal and gastric cancer. Br. J. Cancer, 62: 1023–1025, 1990.
27.
MiwaM., UraM., NischidaM., SawadaN., IshikawaT., MoriK., ShimmaN., UmedaI., IshitsukaH.: Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumors by enzymes concentrated in human liver and cancer tissue. Eur. J. Cancer, 34: 1274–1281, 1998.
28.
MorimotoT., OgawaM., OritaK., SuggimakiK., TogeT., DohiK., NomuraY., MondenY., OgawaN.: Postoperative adjuvant randomized trial comparing chemoendocrine therapy, chemotherapy, and immunotherapy of patients with stage II breast cancer: 5-year results from the Nishinihon Cooperative Study Group of Adjuvant Chemoendocrine Therapy for Breast Cancer (ACETBC) of Japan. Eur. J. Cancer, 32A: 235–242, 1996.
29.
OhashiO., YamamotoM., IshidaH., TakaseS., HasegawaK., MoritaS., KamigakiT., SaitohY.: Retrospective analysis of postoperative chemotherapy with UFT against pancreatic cancer. Jpn. J. Cancer Chemother., 22: 933–939, 1995.
30.
OkabeH., TokoT., SaitoH., NakanoK., FujiokaA., YuasaC., TakedaS., UnemiN.: Augmentation of the chemotherapeutic effectiveness of UFT, a combination of tegafur 1-(2-terahydrofuryl)-5-fluorouracil with uracil, by oral leucovorin. Anticancer Res., 17: 157–164, 1997.
31.
OtaK., TaguchiT., KimuraK.: Report on nationwide pooled data and cohort investigation in UFT phase II study. Cancer Chemother. Pharmacol., 22: 333–338, 1988.
32.
PazdurR., LassereY., RhodesV, AjaniJ.A., SugarmanS.M., PattY.Z., JonesD.V.Jr., MarkovitzA.B., AbbruzzeseJ.L., BreadyB., LevinB.: Phase II trial of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinoma. J. Clin. Oncol., 12: 2296–2300, 1994.
33.
PazdurR., RiveraE., Diaz-CantonE., LassereY., BreadyB., WinR., AjaniJ.A.: Phase I trial of UFT (uracil: tegafur) with leucovorin: 14-day schedule (Abst. n. 1568). Proc. Am. Soc. Clin. Oncol., 14: 482, 1995.
34.
PazdurR., CovingtonW.P., BrownN.S., LassereY., Diaz-CantonE., HoD.H.: Comparative steady-state pharmacokinetics of oral UFT versus protracted intravenous 5-fluorouracil (FU) (Abst. n. 1498). Proc. Am. Soc. Clin. Oncol., 15: 474, 1996.
35.
RustumY.M., HarstrickA., CaoS., VanhoeferU., YinM.B., WilkeH., SeeberS.: Thymidylate synthase inhibitors in cancer therapy: direct and indirect inhibitors. J. Clin. Onco., 15: 389–400, 1997.
36.
SahashiM., OnoY., MatsuuraO., OhshimaS., FukushimaM.: Combination chemotherapy for advanced urothelial tract carcinoma. Cancer Chemother. Pharmacol., 30: 59–62, 1992.
37.
SakamotoS., TagaH., UchikoshiT., KudoH., SuzukiS., SugiuraY., KuwaK., EndoY.: Synergistic effect of oral UFT in combination with cisplatin on DNA synthesis in rat hepatocarcinoma. Anticancer Res., 13: 631–634, 1993.
38.
TashiroH., NomuraY., OhsakiA.: A double-blind comparative study of tegafur (FT) and UFT (a combination of tegafur and uracil) in advanced breast cancer. Jpn. J. Clin. Oncol., 24: 212–217, 1994.
39.
TerachiT., OkadaY., TakeuchiH., YoshidaO.: Long-term complete response of multiple lung metastases from renal cell carcinoma induced by combination therapy with interferon-alpha and UFT: a case report. Acta Urol. Jap., 39: 353–355, 1993.
40.
WadaH., HitomiS., TeramatsuT.: Adjuvant chemotherapy after complete resection in non small cell lung cancer. J. Clin. Oncol., 14: 1048–1054, 1996.
41.
WadaT., NishiyamaK., MaedaM., HaraS., TanakaN., YasutomiM., KuritaT.: Combined chemoendocrine treatment with tegafur and tamoxifen for advanced renal cell carcinoma. Anticancer Res., 15: 1581–1584, 1995.
42.
ZalcbergJ.R., CunninghamD., CutsemV., FrancoisE., SchornagelJ., AdenisA., GreenM., IvensonA., AzabM., SeymourI.: ZD1694: A novel thymidylate synthase inhibitor with substantial activity in the treatment of patients with advanced colorectal cancer. J. Clin. Onco., 14: 716–721, 1996.
